Description
Etopozid (Etoposide) Concentrate for Infusions 20 mg/ml – 5 ml Vial
Composition:
Each 5 ml vial contains 100 mg of etoposide as the active ingredient. Other ingredients include citric acid, polysorbate 80, and sodium chloride.
Mechanism of Action:
Etopozid (etoposide) interferes with the growth of cancer cells by inhibiting topoisomerase II, an essential enzyme in DNA replication, ultimately leading to cancer cell death.
Pharmacological Properties:
Etopozid (etoposide) is a cytotoxic agent that belongs to the class of topoisomerase inhibitors. It exerts its antineoplastic effects by disrupting DNA synthesis in rapidly dividing cancer cells.
Indications for Use:
Etopozid (etoposide) concentrate for infusions is indicated for the treatment of various cancers, including lung cancer, testicular cancer, and lymphomas.
Contraindications:
This medication is contraindicated in patients with a known hypersensitivity to etoposide or any of the other ingredients. It should not be used in pregnant women due to potential fetal harm.
Side Effects:
Common side effects of Etopozid (etoposide) may include nausea, vomiting, hair loss, myelosuppression, and increased susceptibility to infections.
Usage Instructions:
Etopozid (etoposide) concentrate for infusions should be administered intravenously by experienced healthcare professionals. The dosage is determined based on the patient’s condition and is infused slowly to minimize side effects.
Benefits Compared to Analogues:
Etopozid (etoposide) has demonstrated superior efficacy in combination therapies for small cell lung cancer, leading to improved overall survival rates and tumor response compared to standard treatments.
Suitable Patient Groups:
Etopozid (etoposide) can be used in adult patients for various cancer types. Dosing adjustments may be required for elderly individuals based on their overall health and organ function.
Storage and Shelf Life:
Etopozid (etoposide) concentrate should be stored at controlled room temperature away from light and moisture. Check the product packaging for the expiration date and do not use expired vials.
Packaging Description:
Etopozid (etoposide) concentrate for infusions is supplied in 5 ml vials containing 100 mg of the active ingredient. Each vial is labeled with the necessary product information and should be inspected for any signs of damage before use.
Clinical Evidence and Proven Effectiveness:
Etoposide has been extensively studied in clinical trials, with research showing its effectiveness in treating small cell lung cancer. Studies published in the Journal of Clinical Oncology have demonstrated significant improvements in survival rates and tumor response with etoposide-based therapies.
